Jim Simons
AARD

Jim Simons’s Aardvark Therapeutics AARD Stock Holding History

Jim Simons’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$267K Buy
+70,792
New +$734K ﹤0.01% 2834

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jim Simons's AARD Position: Q1 2026 in Review

Jim Simons opened a new position in Aardvark Therapeutics (AARD) in Q1 2026: 70,792 shares worth $267K. The stake represents ﹤0.01% of the portfolio and ranks #2834 among its holdings.

79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Jim Simons held 70,792 shares of Aardvark Therapeutics worth $267K as of Q1 2026.
  • Aardvark Therapeutics was a new Jim Simons position in Q1 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2834 holding.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.